Shire closer to deal to buy Baxalta, report says
Baxalta's board rejected an all-share bid from Shire in August
Drug maker Shire has made a new acquisition offer for peer Baxalta International that is roughly in line with the latter's valuation expectations, making a deal in the coming weeks likely, people familiar with the matter said.
Reuters reported that an agreement would successfully end Dublin-based Shire's five-month pursuit of Illinois-based Baxalta and create one of the world's leading specialists in rare diseases.
Baxalta's board rejected an all-share offer from Shire in August, saying it...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Nadine O’Regan: Fishing for compliments at our own funerals
Jaws it ain’t, but a brush with an angry weever fish in the shallows of the Atlantic Ocean prompts some musings on mortality
Emer McLysaght: Take it or leave it, Father’s Day is not an issue
We don’t have to ban Father’s Day, we just have to realise it’s not for everyone and allow people to choose whether or not to celebrate
Analysis: Moral hazard at the heart of public health leaders’ reluctance to begin use of rapid antigen testing
Rapid tests may be useful in certain situations, but it’s all about the context in which they are deployed
Elaine Byrne: What structural defect means taxpayers always carry the can?
The homeowners in the mica scandal must be compensated, but the taxpayer deserves some consideration too